Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
Are there specific organisms other than s. aureus in which you offer indefinite antibiotic suppression in medically treated prosthetic valve endocarditis?
Related Questions
How long would you continue intravenous suppressive therapy following surgical washout for a patient with an LVAD as destination therapy, found to have an outflow tract fluid collection secondary to fluoroquinolone-resistant pseudomonas aeruginosa?
Do you treat with antibiotics active against methicillin-resistant staphylococci when a patient's culture grows non-lugdunensis, coagulase-negative staphylococci that tests susceptible to oxacillin by phenotypic testing, given the low constitutive PbP2A production of most CoNS?
What factors do you consider when choosing between baloxavir and oseltamivir for treating patients with influenza?
Do you recommend procalcitonin to help convince other providers to stop antibiotics in patients with pneumonia in whom a non-infectious diagnosis is strongly suspected?
Do you use CNS dosing of antibiotics for any portion of the treatment course in patients with infective endocarditis who have cerebral emboli?
What is your approach to managing antimicrobial therapy for intra-abdominal infections to avoid unnecessary double anaerobic coverage, in light of associated risks and guidelines?
Is there a specific criteria that you use to determine if a patient with respiratory symptoms should have a multiplex respiratory test performed?
How have the results of the BALANCE trial, which demonstrated the noninferiority of 7 days of antibiotics compared to 14 days for non-S. aureus bloodstream infections, influenced your practice?
When would you consider an all-oral regimen for patients with Whipple's disease instead of the typical parenteral treatment with ceftriaxone or meropenem followed by oral TMP/SMX?
How do you utilize (1,3)-beta-D-glucan in CSF for diagnosing and monitoring non-cryptococcal CNS fungal infections?
